San Francisco, United States
Deciduous Therapeutics, founded in 2018, is making strides in the Biopharma, Biotechnology, and Health Care sectors with its innovative approach to enhancing human longevity. The company is headquartered in the United States and has recently positioned itself as a potential leader in the development of immune-modulatory therapies aimed at promoting a healthy lifespan.
Deciduous targets the accumulation of senescent cells, known to drive age-related diseases through inflammation and metabolic disruptions. By discovering novel molecules that activate the body's own immune surveillance to remove these cells, the company offers a promising solution to improve health-span.
Their most recent funding achievement was a $10.00M Seed Round investment on 31 December 2022, with participation from notable investors such as Bold Capital Partners, Owl Capital, Healthspan Capital, and the Humboldt Fund. These substantial endorsements highlight investor confidence in Deciduous's innovative therapeutic developments.
